Exploring Clinically Meaningful Advanced Therapies in Neurodegenerative Diseases

Milica G. Kramberger[1,2]

[1]Department of neurology, University Medical Center Ljubljana, Slovenia
[2]Faculty of medicine, University of Ljubljana, Slovenia

Neurodegenerative diseases like Parkinson's and Alzheimer's present a significant challenge in healthcare, impacting millions worldwide. Developing advanced therapies that target symptoms effectively and alter disease progression is crucial for improving the quality of life for patients. In Parkinson's disease, device-aided therapies have emerged as a promising frontier in treatment. Deep brain stimulation (DBS) and levodopa-carbidopa intestinal gel (LCIG) infusion represent cutting-edge approaches that provide substantial benefits for patients with advanced Parkinson's symptoms not adequately controlled by medication alone. DBS involves implanting electrodes in specific areas of the brain to regulate abnormal neural activity, leading to reduced motor fluctuations and dyskinesia. Similarly, LCIG infusion delivers a continuous supply of levodopa directly to the small intestine od subcutaneously, offering smoother symptom control compared to oral medication.

Concurrently, the search for disease-modifying treatments in Alzheimer's disease has been a focal point in neurology research. Targeting underlying mechanisms such as beta-amyloid and tau protein accumulation is crucial in slowing disease progression. Emerging therapies like monoclonal antibodies, tau aggregation inhibitors aim to address these pathologies and potentially alter the course of Alzheimer's. Clinical trials evaluating these treatments have shown promising results in reducing cognitive decline and enhancing patient outcomes.

The combination of device-aided therapies for Parkinson's and disease-modifying treatments for Alzheimer's marks a paradigm shift in neurodegenerative disease management. By harnessing innovative technologies and pharmacological interventions, clinicians can offer more personalized and effective care to patients. As research continues to advance, the prospect of achieving clinically meaningful outcomes in neurodegenerative diseases becomes increasingly tangible. Embracing these transformative therapies not only enhances symptomatic relief but also holds the promise of slowing disease progression and improving the overall prognosis for individuals affected by these debilitating conditions.